Soliris® (eculizumab) available on PBS from 1 March 2022

The program that subsidises Soliris® for patients with a rare condition called paroxysmal nocturnal haemoglobinuria (PNH) is changing. Until now, we have subsidised Soliris® under the Life Saving Drugs Program. From 1 March 2022, this will change to the Pharmaceutical Benefits Scheme (PBS).

Date published:
Type:
News
Audience:
General public

From 1 March 2022, eculizumab (Soliris®) will be available under the Section 100 Highly Specialised Drugs (HSD) program of the Pharmaceutical Benefits Scheme. Until now, we have subsidised Soliris® under the Life Saving Drugs Program.

This change applies to all existing patients with paroxysmal nocturnal haemoglobinuria (PNH). 

If you are a patient with PNH, make an appointment to see your treating physician to transition you to the new program.

If you are a prescriber treating patients with PNH, read our fact sheet to find out how to transition your patients.

For more details about the changes to Soliris® access for PNH patients, see our fact sheets for:

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.